Elimination of hepatitis c in Turkey

This manuscript examines the epidemiological patterns, transmission routes, and genotypic distribution of hepatitis C virus (HCV) in Türkiye, highlighting national progress toward elimination targets set by the World Health Organization (WHO). The main objective is to evaluate the effectiveness of national screening, diagnostic, and treatment strategies, with a focus on the scale-up of direct-acting antiviral (DAA) therapies and their associated cost-effectiveness. Drawing on recent multicenter and population-based studies, the paper outlines the shifting prevalence of HCV geno types, particularly among high-risk populations such as people who inject drugs (PWID), prisoners, and individuals undergoing hemodialysis. The analysis demon strates that genotype 1b remains predominant, though genotype diversity is increas ing due to migration and changing transmission dynamics. Findings reveal that despite improved availability of DAA treatments and health policy initiatives like the 2018–2023 National Viral Hepatitis Program, gaps persist in diagnostic follow-up and referral. The manuscript emphasizes the dual approach of micro- and macro elimination, advocating for integrated care models, increased physician engagement, and enhanced awareness efforts. Projections suggest that achieving WHO goals is feasible in Türkiye if testing and treatment rates significantly improve. Ultimately, this study underscores the necessity of sustained political commitment, intersectoral collaboration, and targeted public-health interventions to reduce HCV-related mor bidity and mortality by 2030.